RESUMO
La eritrodisestesia palmoplantar es una reacción adversa que se asocia a la administración de docetaxel y fluoropirimidinas. La actividad de la enzima dihidropirimidina deshidrogenasa (DPD) determina la tasa de catabolismo del 5-Fluorouracilo (5-FU) y está sujeta a variabilidad interindividual y polimorfismo genético. Por tanto, los pacientes con deficiencia de DPD presentan un mayor riesgo de toxicidad. Presentamos el caso de un paciente tratado con docetaxel, oxaliplatino y 5-FU (esquema FLOT) que presentó toxicidad cutánea moderada y del que se sospechó deficiencia de DPD.(AU)
Palmoplantar erythrodysesthesia is an adverse event associated with the administration of docetaxel and fluoropyrimidines. The activity of the enzyme dihydropyrimidine dehydrogenase (DPD) determines the rate of catabolism of 5-Fluorouracil (5-FU) and is subject to interindividual variability and genetic polymorphism. Therefore, patients with DPD deficiency present an increased risk of toxicity. We present the case of a patient treated with docetaxel, oxaliplatin and 5-FU (FLOT scheme) who presented moderate skin toxicity and who was suspected of DPD deficiency.(AU)
Assuntos
Humanos , Masculino , Docetaxel , Fluoruracila , Hipestesia , Dor , Pacientes Internados , Exame FísicoRESUMO
Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en agosto, octubre y noviembre de 2019, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in August, October and November of 2019, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the producto
Assuntos
Humanos , Avaliação de Medicamentos , Prova Pericial , Órgãos GovernamentaisRESUMO
Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento publicados en marzo y abril de 2018, considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in March, April and May of 2018, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product
Assuntos
Humanos , Avaliação de Medicamentos/métodos , Equipamentos e Provisões/normas , Avaliação de Medicamentos/normas , Arginina/uso terapêutico , Buprenorfina/uso terapêutico , Antígenos CD34 , Cicloexanos , Lamivudina , Hidroxiureia , Toxinas Botulínicas Tipo A , 58011RESUMO
Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en diciembre de 2018, enero y febrero de 2019, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in December 2018, January and February of 2019 , and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product
Assuntos
Humanos , Avaliação de Medicamentos/métodos , Aprovação de Drogas/métodos , Avaliação de Medicamentos/instrumentação , AnalgésicosRESUMO
Se reseñan los medicamentos evaluados y con dictamen positivo por la comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en septiembre, octubre y noviembre de 2018. Se trata de opiniones técnicas positivas previas a la autorización y puesta en el mercado del medicamento
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in September, October and November of 2018, and considered of interest to the healthcare profesional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product
Assuntos
Humanos , Criança , Adolescente , Adulto Jovem , Adulto , Avaliação de Medicamentos/métodos , Avaliação de Medicamentos/normas , Antígenos de Superfície/análise , Vírus da Influenza A/efeitos dos fármacos , Vírus da Influenza B/efeitos dos fármacos , Avaliação de Medicamentos/legislação & jurisprudênciaRESUMO
Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en diciembre de 2017, enero y febrero de 2018, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in December of 2017, January and February of 2018, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product
Assuntos
Denominação Comercial do Medicamento , Aprovação de Drogas , Preparações Farmacêuticas/administração & dosagem , Comissão para Avaliação de Medicamentos , Espanha , Comercialização de ProdutosRESUMO
Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en marzo, abril y mayo 2017, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in March, April and May of 2017, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product (AU)
Assuntos
Humanos , Aprovação de Drogas/estatística & dados numéricos , Avaliação de Medicamentos/tendências , Drogas em Investigação , Ensaios de Uso Compassivo , Terapia Biológica/estatística & dados numéricos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologiaRESUMO
Se reseñan los medicamentos evaluados y con dictamen positivo por la comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en marzo, abril y mayo de 2016. Se trata de opiniones técnicas positivas previas a la autorización y puesta en el mercado del medicamento
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in March, April and May of 2016, and considered of interest to the healthcare profesional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product
Assuntos
Humanos , Avaliação de Medicamentos , Aprovação de Drogas , Drogas em Investigação/farmacocinética , Vacinas contra Influenza , Ceftazidima , Rilpivirina , TenofovirRESUMO
Se reseñan los medicamentos evaluados y con dictamen positivo por la comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en junio y julio de 2015. Se trata de opiniones técnicas positivas previas a la autorización y puesta en el mercado del medicamento
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in june and july of 2015, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product
Assuntos
Feminino , Humanos , Masculino , Avaliação de Medicamentos/legislação & jurisprudência , Avaliação de Medicamentos/métodos , Avaliação de Medicamentos/normas , Adjuvantes Farmacêuticos/economia , Adjuvantes Farmacêuticos/uso terapêutico , Hipercolesterolemia/tratamento farmacológico , Hepatite B/tratamento farmacológico , Hepatite B/imunologia , Avaliação de Medicamentos/economia , Avaliação de Medicamentos/tendências , Avaliação de Medicamentos , Adjuvantes Farmacêuticos/normas , Resultado do Tratamento , Plasmodium falciparumRESUMO
Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hecho públicos en septiembre, octubre y noviembre de 2014, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in September, October and November of 2014, and considered of interest to the healthcare profesional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product
Assuntos
Humanos , Masculino , Feminino , Avaliação de Medicamentos/legislação & jurisprudência , Avaliação de Medicamentos/métodos , Avaliação de Medicamentos , Dermatite Fototóxica/epidemiologia , Dermatite Fototóxica/prevenção & controle , Avaliação de Medicamentos/instrumentação , Avaliação de Medicamentos/tendências , Avaliação de Eficácia-Efetividade de Intervenções , Terapia Combinada/instrumentação , Terapia Combinada/métodosRESUMO
Se reseñan los medicamentos ya evaluados por la Agencia Española de Medicamentos y Productos Sanitarios, considerados de mayor interés para el profesional sanitario en el ámbito hospitalario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento
The drugs assessed by the Spanish Agency for Medicines and Health Products made public in , and considered of interest in hospital healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product
Assuntos
Humanos , Aprovação de Drogas , Avaliação de Medicamentos , Aplicação de Novas Drogas em Teste , Serviço de Farmácia HospitalarRESUMO
Se reseñan los medicamentos ya evaluados por la Agencia Española de Medicamentos y Productos Sanitarios hechos públicos en los meses de junio y julio de 2013, y considerados de mayor interés para el profesional sanitario en el ámbito hospitalario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products made public in June and July of 2013, and considered of interest in hospital healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product (AU)
Assuntos
Humanos , Aprovação de Drogas , Medicamentos de Referência , Assistência FarmacêuticaRESUMO
Se reseñan los medicamentos ya evaluados por la Agencia Española de Medicamentos y Productos Sanitarios hechos públicos en el segundo trimestre de 2013, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
Medications are reviewed and evaluated by the Spanish Agency of Medicines and Health Products made public in the second quarter of 2013, and considered of greatest interest to the clinician. It is positive technical opinions that are pre-authorization and placing on the market of the product (AU)
Assuntos
Humanos , Drogas em Investigação , Avaliação de Medicamentos , Hormônio do Crescimento Humano , Fator VIII , Condrócitos , DextrometorfanoRESUMO
Se reseñan los medicamentos ya evaluados por la Agencia Española de Medicamentos y Productos Sanitarios hechos públicos en el último trimestre de 2012, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products made public in the last quarter of 2012, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product (AU)
Assuntos
Humanos , Medicamentos de Referência , Drogas em InvestigaçãoRESUMO
Se reseñan los medicamentos ya evaluados por la Agencia Española de Medicamentos y Productos Sanitarios hechos públicos en el 1er trimestre de 2012, y considerados de mayor interés para el profesional sanitario en el ámbito hospitalario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products made public in the first trimester of 2012, and considered of interest in hospital healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product (AU)
Assuntos
Humanos , Drogas em Investigação/análise , Granisetron/uso terapêutico , Agonistas do Receptor de Serotonina/análise , Vacinas Meningocócicas/uso terapêutico , Somatostatina/uso terapêutico , Antraciclinas/uso terapêuticoRESUMO
Se reseñan los medicamentos ya evaluados por la Agencia Española de Medicamentos y Productos Sanitarios hechos públicos en el tercer trimestre de 2011, y considerados de mayor interés para el profesional sanitario en el ámbito hospitalario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products made public in the third quarter of 2011, and considered of interest in hospital healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product (AU)
Assuntos
Humanos , Drogas em Investigação , Antivirais/farmacologia , Antibacterianos/farmacologia , Hipoglicemiantes/farmacologia , Inibidores da Transcriptase Reversa/farmacologia , Bloqueadores do Receptor Tipo 1 de Angiotensina II/farmacologia , Antagonistas de Androgênios/farmacologiaRESUMO
Se reseñan los medicamentos ya evaluados por la Agencia Española de Medicamentos y Productos Sanitarios hechos públicos en el primer trimestre de 2011, y considerados de mayor interés para el profesional sanitario en el ámbito hospitalario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products made public in the first quarter of 2011, and considered of interest in hospital healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product (AU)
Assuntos
Humanos , Medicamentos de Referência , Drogas em Investigação , Pesquisa Biomédica/tendênciasRESUMO
Concomitant administration of statins with food may alter statin pharmacokinetics or pharmacodynamics, increasing the risk of adverse reactions such as myopathy or rhabdomyolysis or reducing their pharmacological action. This paper reviews major interactions between statins and dietary compounds. Consumption of pectin or oat bran together with Lovastatin reduces absorption of the drug, while alcohol intake does not appear to affect the efficacy and safety of Fluvastatin treatment. Grapefruit juice components inhibit cytochrome P-4503A4, reducing the presystemic metabolism of drugs such as Simvastatin, Lovastatin and Atorvastatin. Follow-up studies on the therapeutic effect of statins in patients consuming a Mediterranean-style diet are necessary to assure the correct prescription because the oil-statin and minor oil compound-statin possible interactions have been only briefly studied. Preliminary study suggests that olive oil can increase the hypolipaemiant effect of Simvastatin with respect sunflower oil. The consumption of polyunsaturated rich oils, throughout the cytochrome P- 450 activation could decrease the half-life of some statins and therefore their hypolipaemic effects. The statins and n-3 fatty acids combined therapy gives rise to pharmacodinamic interaction that improves the lipid profile and leads greater cardioprotection. Although statins are more effective in high endogenous cholesterol production subjects and plant sterols are more effective in high cholesterol absorption efficacy subjects, plant esterols-statins combined therapy generates very positive complementary effects. This review ends suggesting possible diet-stain interactions that require further investigations (e.g. types of olive oils, fruit juices other than grapefruit, fibre or consumption of alcoholic beverages rich in polyphenols or ethanol).
Assuntos
Interações Alimento-Droga , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacocinética , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Hiperlipidemias/tratamento farmacológico , Bebidas , Citrus paradisi , Ácidos Graxos , Humanos , Hiperlipidemias/sangue , FitosteróisRESUMO
Concomitant administration of statins with food may alter statin pharmacokinetics or pharmacodynamics, increasing the risk of adverse reactions such as myopathy or rhabdomyolysis or reducing their pharmacological action. This paper reviews major interactions between statins and dietary compounds. Consumption of pectin or oat bran together with Lovastatin reduces absorption of the drug, while alcohol intake does not appear to affect the efficacy and safety of Fluvastatin treatment. Grapefruit juice components inhibit cytochrome P-4503A4, reducing the presystemic metabolism of drugs such as Simvastatin, Lovastatin and Atorvastatin. Follow-up studies on the therapeutic effect of statins in patients consuming a Mediterranean-style diet are necessary to assure the correct prescription because the oil-statin and minor oil compound-statin possible interactions have been only briefly studied. Preliminary study suggests that olive oil can increase the hypolipaemiant effect of Simvastatin with respect sunflower oil. The consumption of polyunsaturated rich oils, throughout the cytochrome P- 450 activation could decrease the half-life of some statins and therefore their hypolipaemic effects. The statins and n-3 fatty acids combined therapy gives rise to pharmacodinamic interaction that improves the lipid profile and leads greater cardioprotection. Although statins are more effective in high endogenous cholesterol production subjects and plant sterols are more effective in high cholesterol absorption efficacy subjects, plant esterols-statins combined therapy generates very positive complementary effects. This review ends suggesting possible diet-stain interactions that require further investigations (e.g. types of olive oils, fruit juices other than grapefruit, fibre or consumption of alcoholic beverages rich in polyphenols or ethanol) (AU)
La administración conjunta de estatinas y alimentos puede producir reacciones adversas, como miopatía o rabdomiolisis, o reducir su acción farmacológica. Este artículo revisa las interacciones más importantes entre estatinas y componentes dietéticos. El consumo de pectina o de salvado de avena junto con Lovastatina reduce la absorción del fármaco, mientras que la ingesta de alcohol no afecta la eficacia ni la seguridad del tratamiento con Fluvastatina. Algunos componentes del zumo de pomelo inhiben el citocromo P-450 A4, reduciendo el metabolismo presistémico de la Simvastatina, Lovastatina y Atorvastatina. Se necesitan estudios de seguimiento sobre los efectos terapéuticos de las estatinas en pacientes que consumen dieta Mediterránea para asegurar la correcta prescripción, ya que no existen estudios de posibles interacciones entre el aceite o sus compuestos minoritarios y las estatinas. Un estudio preliminar sugiere que el aceite de oliva respecto al de girasol incrementa la acción hipolipemiante de la Simvastatina. El consumo de aceites ricos en ácidos grasos poliinsaturados, a través de la activación de citocromo P-450, podría disminuir la vida media de las estatinas y, por tanto, sus efectos hipolipemiantes. La terapia combinada estatinas y ácidos grasos n-3 da lugar a una interacción farmacodinámica que mejora el perfil lipídico e induce mayor cardioprotección. Aunque las estatinas son más efectivas en individuos con alta producción endógena de colesterol y los esteroles de plantas en aquellos que presentan mayor absorción de colesterol, la terapia conjunta induce efectos complementarios muy positivos. Se concluye la revisión sugiriendo más estudios en aquellas interacciones entre alimentos (ej. tipos de aceite de oliva, de zumos, de fibra o el consumo de bebidas alcohólicas ricas en polifenoles o etanol) y estatinas (AU)
